Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients
Status:
Withdrawn
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that switching kidney transplant patients on
tacrolimus/sirolimus long-term maintenance immunosuppressive drug regimens to
tacrolimus/everolimus, will not only be safe, but will lead to better kidney function than
patients staying on tacrolimus/sirolimus due to the lower potential of everolimus to enhance
calcineurin inhibitors toxicity and/or its ability to even reverse some of the negative
effects of calcineurin inhibitors on vascular endothelial and kidney function. To test this
hypothesis vascular endothelial biomarkers will be analyzed in blood plasma samples and
kidney dysfunction biomarkers in urine samples via liquid chromatography tandem mass
spectrometry to evaluate whether switching kidney transplant patients on tacrolimus/sirolimus
to tacrolimus/everolimus will lead to better kidney and endothelial function after one year
and two years.